BioAge Labs to Present at Jefferies Global Healthcare Conference in London
BioAge Labs (NASDAQ: BIOA) will present at the Jefferies Global Healthcare Conference in London on November 17–20, 2025. The company said CEO Kristen Fortney, PhD, and CFO Dov Goldstein, MD, will join a fireside chat on Monday, November 17 from 7:30–7:55 AM ET (12:30–1:00 PM GMT) and will hold one-on-one meetings.
Investors can watch a live webcast by registering via the company link and access replays in the investor section at https://ir.bioagelabs.com/; replays will be archived for 30 days after the presentations.
BioAge Labs (NASDAQ: BIOA) si presenterà alla Jefferies Global Healthcare Conference a Londra dal 17 al 20 novembre 2025. L'azienda ha comunicato che la CEO Kristen Fortney, PhD, e il CFO Dov Goldstein, MD, parteciperanno a una chiacchierata informale sul lunedì 17 novembre dalle 7:30 alle 7:55 AM ET (12:30–13:00 GMT) e avranno riunioni individuali.
I investitori possono guardare una trasmissione in diretta registrandosi tramite il link aziendale e accedendo alle repliche nella sezione investitori all'https://ir.bioagelabs.com/; le repliche saranno archiviate per 30 giorni dopo le presentazioni.
BioAge Labs (NASDAQ: BIOA) se presentará en la Jefferies Global Healthcare Conference en Londres del 17 al 20 de noviembre de 2025. La empresa indicó que la CEO Kristen Fortney, PhD, y el CFO Dov Goldstein, MD, participarán en una conversación junto al fuego el lunes 17 de noviembre de 7:30 a 7:55 AM ET (12:30–13:00 GMT) y mantendrán reuniones one-on-one.
Los inversores pueden ver una transmisión en vivo registrándose a través del enlace de la empresa y acceder a las repeticiones en la sección de inversores en https://ir.bioagelabs.com/; las repeticiones quedarán archivadas por 30 días después de las presentaciones.
BioAge Labs (NASDAQ: BIOA) 는 런던에서 열리는 Jefferies Global Healthcare Conference에서 2025년 11월 17–20일에 발표할 예정입니다. 회사는 CEO Kristen Fortney, PhD, и CFO Dov Goldstein, MD가 11월 17일 월요일 7:30–7:55 AM ET(12:30–13:00 GMT) 의 fireside chat에 참여하고 1대1 미팅을 가질 것이라고 밝혔습니다.
투자자는 라이브 webcast를 시청하기 위해 회사 링크를 통해 등록하고 https://ir.bioagelabs.com/의 투자자 섹션에서 다시 보기를 이용할 수 있으며; 재생은 프레젠테이션 후 30일 동안 보관됩니다.
BioAge Labs (NASDAQ: BIOA) participera à la Jefferies Global Healthcare Conference à Londres du 17 au 20 novembre 2025. L'entreprise a indiqué que la CEO Kristen Fortney, PhD, et le CFO Dov Goldstein, MD, prendront part à une conversation informelle le lundi 17 novembre de 7h30 à 7h55 ET (12h30–13h00 GMT) et auront des réunions en tête-à-tête.
Les investisseurs peuvent regarder une webdiffusion en direct en s'inscrivant via le lien de l'entreprise et accéder aux rediffusions dans la section investisseurs sur https://ir.bioagelabs.com/; les rediffusions seront archivées pendant 30 jours après les présentations.
BioAge Labs (NASDAQ: BIOA) wird auf der Jefferies Global Healthcare Conference in London vom 17. bis 20. November 2025 auftreten. Das Unternehmen gab bekannt, dass CEO Kristen Fortney, PhD, und CFO Dov Goldstein, MD, an einer Fireside-Chat am Montag, dem 17. November von 7:30–7:55 Uhr ET (12:30–13:00 GMT) teilnehmen und Einzelgespräche führen werden.
Investoren können einen Live-Webcast ansehen, indem sie sich über den Unternehmenslink registrieren und die Wiederholungen im Bereich Investor unter https://ir.bioagelabs.com/ aufrufen; die Aufzeichnungen werden 30 Tage nach den Präsentationen archiviert.
بيوإيج لابز (ناسداك: BIOA) ستقدم في مؤتمر Jefferies Global Healthcare في لندن في 17–20 نوفمبر 2025. قالت الشركة إن الرئيسة التنفيذية Kristen Fortney، PhD، والمدير المالي Dov Goldstein، MD، سينضمون إلى حديث بجلسة حميمة يوم الاثنين 17 نوفمبر من 7:30–7:55 صباحاً بتوقيت شرق الولايات المتحدة (12:30–13:00 GMT) وسيجريان اجتماعات فردية.
يمكن للمستثمرين مشاهدة بث حي عن طريق التسجيل عبر رابط الشركة والوصول إلى الإعادات في قسم المستثمرين على https://ir.bioagelabs.com/; ستُؤرشف الإعادات لمدة 30 يوماً بعد العروض.
- None.
- None.
EMERYVILLE, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Jefferies Global Healthcare Conference in London, November 17–20, 2025.
Kristen Fortney, PhD, CEO and co-founder, and Dov Goldstein, MD, CFO, are scheduled to participate in a fireside chat on Monday, November 17 from 7:30 - 7:55 AM ET (12:30 - 1 PM GMT), and will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for obesity and cardiovascular risk factors. A Phase 1 SAD/MAD trial of BGE-102 is underway, with initial SAD data anticipated by end of year. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
FAQ
When will BioAge Labs (BIOA) present at the Jefferies Global Healthcare Conference in London?
What time is the BioAge (BIOA) fireside chat on November 17, 2025?
Who will represent BioAge Labs (BIOA) at the Jefferies conference on November 17, 2025?
How can investors watch the BioAge (BIOA) presentation webcast on November 17, 2025?
Where will BioAge (BIOA) replay recordings be available and for how long after November 17, 2025?
